Related Experiment Videos
[Appetite suppressants and heart valve disorders]
Archives Des Maladies Du Coeur Et Des Vaisseaux
|October 26, 1999
Summary
Serotonin-based appetite suppressants like fenfluramine caused serious heart valve issues and pulmonary hypertension. Further research is needed to understand the long-term risks and true incidence of these cardiovascular complications.
Area of Science:
- Cardiology
- Pharmacology
- Toxicology
Context:
- Fenfluramine and dexfenfluramine, appetite suppressants targeting serotonin, were withdrawn in 1997 due to severe cardiopulmonary side effects.
- These drugs were linked to primary pulmonary hypertension and valvular heart disease, primarily affecting left-sided valves like the aortic valve.
Purpose:
- To review the cardiopulmonary complications associated with serotoninergic appetite suppressants.
- To discuss the pathological mechanisms, clinical presentation, and diagnostic recommendations for drug-induced valvular heart disease and pulmonary hypertension.
Summary:
- Prolonged exposure (>3 months) to fenfluramine and dexfenfluramine increases the risk of cardiac valve damage and pulmonary hypertension, potentially due to elevated circulating serotonin levels.
- Pathological features resemble carcinoid or ergot alkaloid-induced valve disease, suggesting a common mechanism.
- While initial reports indicated high prevalence of valvular side effects, recent studies suggest lower rates; however, long-term outcomes and true incidence require further investigation.
Impact:
- Highlights the significant cardiovascular risks associated with specific appetite-suppressant medications.
- Underscores the need for clinical surveillance and Doppler echocardiography in patients with prolonged exposure or risk factors.
- Informs ongoing research and epidemiological data collection to fully ascertain the long-term consequences of these drugs.